← Back to News

Medtronic (MDT) Completes $550M Acquisition of Scientia Vascular

positiveManagementMulti dayYahoo Finance ·21 Jun 2026Original article ↗
Oraklio AI Analysis

Company-specific M&A completion can impact near-term sentiment and valuation, though the dashboard tickers provided do not include MDT, limiting direct linkage to an active symbol.

Article

Medtronic (MDT) Completes $550M Acquisition of Scientia Vascular Maham Fatima Sun, June 21, 2026 at 12:53 PM GMT+2 2 min read MDT Medtronic (NYSE: MDT ) is one of the most undervalued NYSE stocks to invest in . On June 12, Medtronic officially completed its acquisition of Scientia Vascular, a Salt Lake City-based medical device firm, in a transaction valued at $550 million. The deal includes potential post-acquisition earn-outs and milestone payments, and it marks a significant move for Medtronic to bolster its neurovascular portfolio by integrating Scientia’s specialized access technologies.

Scientia is recognized for its high-performance guidewires and catheters, which are specifically designed to navigate the complex and tortuous anatomy of the cerebral vasculature. By combining these products with Medtronic’s existing suite of neurovascular tools, the company aims to provide physicians with a more streamlined, integrated platform that simplifies procedures, reduces access challenges, and improves overall procedural efficiency in life-critical stroke treatments. Medtronic (MDT) Completes $550M Acquisition of Scientia Vascular Source: Pixabay This acquisition aligns with Medtronic’s focus on high-growth opportunities and is expected to be minimally dilutive to its adjusted earnings per share in fiscal year 2027, with anticipated accretion thereafter.

Leadership from both companies emphasized that the integration will leverage Medtronic’s global scale to expand the reach of these technologies, ultimately supporting the company’s long-term mission to improve patient outcomes and transform the future of neurovascular care. Medtronic (NYSE:MDT) is a medical technology company that manufactures, distributes, and sells device-based medical services and therapies. It operates under four primary segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock . READ NEXT:  33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .

  Disclosure: None. Follow Insider Monkey on Google News .

Oraklio AI Trading Intelligence

News is just the start.

Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.

Get started free

Already have an account? Sign in →